CARIS LIFE SCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $741.00K, a 37.73% decline year-over-year.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $921.00K, a 35.73% decline year-over-year.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $3.86M, a 1330.74% increase year-over-year.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.15M, a 75.49% increase year-over-year.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $7.64M, a 399.28% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.53M, a 17.96% decline from fiscal 2023.
- CARIS LIFE SCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.86M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $741.00K 10-Q · filed 2026-08-05 | $6.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $921.00K 10-Q · filed 2026-05-08 | $7.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.64M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-05 | $4.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.19M 10-Q · filed 2026-08-05 | $3.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.43M 10-Q · filed 2026-05-08 | $2.75M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.53M 10-K · filed 2026-03-03 |
| 2024-09-30 | $657.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $393.00K 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $1.86M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |